Piper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.37 -5.27%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 17
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 17
Join SI Premium – FREE
Piper Jaffray initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $21.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens
- Macquarie Starts China Jushi Co Ltd (600176:CH) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
